ALLMedicine™ Chronic Myelogenous Leukemia Center

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

May 12th, 2022 - T cell dysfunction is a common characteristic of patients with myeloid leukemia and is closely related to clinical efficacy and prognosis. In order to clarify the mechanisms leading to the T cell dysfunction, we characterized the gene expression p...

Apr 30th, 2022 - BACKGROUND Chronic myelogenous leukemia (CML) is a malignant myeloproliferative neoplasm of pluripotent stem cell origin. Ophthalmic manifestation as an initial presentation in cases of CML is extremely rare. Frequently, ocular lesions in CML are ...

Apr 25th, 2022 - Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most frequent autoimmune paraneoplastic encephalitis, and is primarily associated with ovarian teratomas. Here, we report the first case of a patient diagnosed with chronic myelogenous...

Sep 25th, 2017 - JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).|2017|Usui N,|administration & dosage,administration & dosage,administration & dosage,administration &...

Nov 15th, 2013 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring m...

Jan 10th, 2012 - Chronic myelogenous leukemia.|2012|O'Brien S,Abboud CN,Akhtari M,Altman J,Berman E,|therapeutic use,diagnosis,drug therapy,therapy,therapeutic use,

Nov 3rd, 2009 - NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.|2009|O'Brien S,Berman E,Borghaei H,Deangelo DJ,Devetten MP,|therapeutic use,diagnosis,drug therapy,surgery,

May 9th, 2008 - Chronic myelogenous leukemia: ESMO clinical recommendations for the diagnosis, treatment and follow-up.|2008|Hochhaus A,Dreyling M, ,|diagnosis,epidemiology,therapy,

May 13th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

May 13th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils ...

Apr 15th, 2022 - Up to nowadays, a standard induction therapy for acute myeloid leukemia(AML) has consisted of cytarabine 100-200 mg per square meter of body surface area(BSA) per day continuous infusion for 7 days with idarubicin 12 mg per square meter or daunoru...

Mar 28th, 2022 - PRIMARY OBJECTIVES: I. To test whether outcomes of patients of age 60 or older with previously untreated non-M3 acute myeloid leukemia treated with azacitidine plus gemtuzumab ozogamicin are sufficient to warrant phase III investigation. II. To es...

Mar 11th, 2022 - PRIMARY OBJECTIVE: I. To determine the efficacy of the regimen, as defined by the rate of complete remission (CR) or CR with incomplete count recovery (CRi). SECONDARY OBJECTIVES: I. To determine efficacy outcomes, including rate of minimal residu...

Oct 6th, 2021 - Ron Bose, MD, PhD, assistant professor in the Division of Oncology at Washington University School of Medicine and the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer. Overall, Bose ...

Sep 9th, 2021 - While late mortality among recipients of allogeneic blood or marrow transplantation (BMT) has decreased over the past 4 decades, life expectancy among these patients remains shorter versus the U.S. population at large, a retrospective cohort study...

Sep 7th, 2021 - Javier Pinilla-Ibarz MD, PhD Chronic myelogenous leukemia ( CML) is a relatively rare leukemia in pediatric population and although allogenic bone marrow transplant used to be commonly used even in the earlier times of TKIs therapy, the superior s.

Aug 17th, 2021 - Rainer Storb, MD Member, Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for...

Aug 17th, 2021 - Andrew D. Zelenetz, MD, PhD, Vice Chair, Medical Informatics, Department of Medicine; Chief, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancie...